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INTRODUCTION
Tumor lysis syndrome (TLS) is a life-threatening
complication most commonly observed in highly
proliferative hematologic malignancies. The rapid
release of intracellular contents causes hyperkalemia,
hyperuricemia, hyperphosphatemia, and secondary
hypocalcemia. The constellation of metabolic
abnormalities can manifest clinically as renal insufficiency,
cardiac arrhythmias, seizures, and death due to
multi-organ failure. Traditionally, TLS is rarely observed in
relatively indolent malignancies such as multiple
myeloma. However, its frequency may be increasing
with the advent of more effective and targeted therapies
such as bortezomib. We herein report a 62-year-old man
with IgA kappa light chain multiple myeloma who
developed two episodes of TLS ten days apart following
a single cycle of bortezomib therapy.

CASE PRESENTATION
A 62-year-old man presented to a local community
hospital with a month of progressive back pain. He was
found to have T11-L4 pathological fractures and was
subsequently found to have an elevated kappa-to-lamba
ratio at 1606 with IgA predominance on the SPEP. Flow
cytometry of the peripheral blood was negative for
plasmablasts. He soon underwent a bone marrow
biopsy with aspirate revealing greater than 90% plasma
cell involvement of the bone marrow. Based on the
workup, he was diagnosed with IgA kappa light chain
multiple myeloma and was initiated on bortezomib
therapy. He was deemed stable for discharge on the
same day that the therapy was initiated given no acute
adverse reactions were observed. Within 24 hours, he
became acutely altered and was readmitted. He was
intubated for airway protection and given intravenous
hydration and broad-spectrum antibiotics prior to being
transferred to our medical intensive care unit. On arrival,
he was anuric and in acute renal failure. His presentation
and laboratory findings met criteria for both clinical and
laboratory TLS (Table 1, Figure 1). He was treated with
rasburicase and started on hemodialysis. His TLS labs
gradually normalized. Broad-spectrum antibiotics were
continued through Day 6 of his hospitalization (8 days
after bortezomib therapy).
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On Day 9 of his hospitalization (11 days after bortezomib
therapy), wide complex tachycardia was noted on
telemetry. He was febrile with a maximum temperature
of 104°F. Repeat laboratory work confirmed a recurrence
of TLS including marked hyperkalemia of 8.6 mmol/L
despite the patient having received hemodialysis earlier
that day (Table 1, Figure 1). His labs were also remarkable
for new leukocytosis and severe metabolic acidosis. He
was promptly treated with rasburicase and broadspectrum antibiotics were restarted. He received medical
treatment for hyperkalemia and was initiated of
continuous venovenous hemodialysis. Yet his telemetry
continued to show wide complex tachycardia, which
evolved into ventricular fibrillation and cardiac arrest.
Advanced cardiovascular life support was performed
with return of spontaneous circulation, but he remained
in tenuous condition with marked hypotension and
diffuse bleeding. His family decided to initiate comfort
measures, and he expired shortly thereafter.

Figure 1. Temporal changes in potassium, creatinine, calcium, phosphate, and urate
concentrations in our patient with IgA kappa light chain multiple myeloma after
receiving bortezomib therapy.

Table 1: Laboratory values in our patient with IgA kappa light chain multiple myeloma after receiving bortezomib therapy.
Number of days
after initiating
bortezomib therapy

Potassium
(mmol/L)

Creatinine
(mg/dL)

Calcium
(mg/dL)

Phosphate
(mg/dL)

Urate (mg/
dL)

LDH (IU/L)

INR

2

4.6

5.5

6.7

6.5

14.1

2011

2.52

3

4.4

5.7

6.3

5.7

8.9

N/A

2.1

4

4.7

6.8

6

6.9

6.4

1229

1.85

5

4.6

6.5

6.6

6.3

N/A

N/A

1.65

6

4.7

5.9

6.7

5.9

3.8

240

1.59

7

3.7

4.7

6.9

5.1

5

197

1.61

8

4.2

4.3

7.9

N/A

N/A

N/A

1.37

9

4.5

4.4

8.2

4.7

3

N/A

1.36

10

4.7

6.7

8.2

6.8

N/A

N/A

1.36

11

8.6

9.5

N/A

11.8

12.2

353

1.6

12

7.1

8.5

8.4

N/A

13.3

848

1.99

FOLLOW-UP
His autopsy revealed pneumonia at the time of death.
Blood cultures drawn shortly before the patient expired
grew Pseudomonas aeruginosa and coagulase-negative
Staphylococcus.

DISCUSSION
Tumor lysis syndrome (TLS) has been reported in patients
with a variety of diagnoses but its incidence is greatest in
highly proliferative hematologic malignancies such as
acute lymphocytic lymphoma or Burkitt’s lymphoma
(5.2-23 % and 14.9%, respectively). 1 In contrast, this
condition is usually rare in patients with multiple myeloma.
The following disease characteristics have been shown to
be associated with the development of TLS in these
patients: immature plasma cell morphology, heavy plasma
cell burden within the bone marrow (plasma cells >70%
of all nucleated cells), high proliferative activity of plasma
cells and cytogenetic abnormality within chromosome
11 or 13. 2 Our patient had a heavy plasma cell burden
within the bone marrow based on his bone marrow
biopsy on his last admission.
Bortezomib is a proteasome inhibitor approved in the US
for treating multiple myeloma and mantle cell lymphoma.
It induces cell death by preventing the degradation of
pro-apoptotic proteins. Officially, bortezomib is thought
to be associated with TLS, but whether or not the therapy
induces TLS is debatable.3 Based on a retrospective study
conducted before the approval of bortezomib, 1% of over
800 multiple myeloma patients treated with other
modalities including cyclophosphamide, dexamethasone,

etoposide, and stem cell transplants developed TLS. 2
This number is strikingly similar to the 1.4% of 496 multiple
myeloma patients who developed TLS following
bortezomib treatment.4 Both studies found an association
between the development of TLS in multiple myeloma
patients and the aforementioned high-risk disease
characteristics. Therefore, it may be that the incidence
of TLS is more strongly associated with this patient
population than with the use of bortezomib itself.
As far as we know, all cases of TLS following bortezomib
therapy have occurred within the first cycle of treatment.5
Furthermore, per our literature search, recurrence of TLS
within a single cycle of treatment has never been
described. Our patient developed the first occurrence of
TLS within 24 hours of bortezomib administration.
Following treatment with rasburicase and hemodialysis,
his TLS labs completely normalized. However, several
days later, he developed a presumed second episode of
TLS with no new known risk factors. The recurrence of
TLS coincided with a new leukocytosis and bacteremia.
The relationships between previous episodes of TLS,
concomitant bacteremia, and the recurrent development
of TLS are unknown.
It may be worthwhile to consider TLS in the differential
diagnosis of hyperkalemia and wide complex tachycardia
in multiple myeloma patients. In our case, the diagnosis
of TLS did not promptly come to mind since recurrence
of TLS is unusual. We believe that it is important to
distinguish TLS-associated hyperkalemia from other
etiologies of hyperkalemia such as acute renal failure or
severe acidosis as the two would require different
treatment regimens.
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CONCLUSION
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